VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19
March 02 2020 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Thursday,
March 19 at 8:30am Eastern Time to report fourth quarter and year
ended December 31, 2019 financial results and to provide a
corporate update.
Thursday March 19th @ 8:30amET |
From the US: |
877-407-9208 |
International: |
201-493-6784 |
Conference ID: |
13699636 |
Webcast: |
https://edge.media-server.com/mmc/p/2ih7jg38 |
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. VBL’s lead oncology product
candidate, ofranergene obadenovec (VB-111), is a first-in-class,
targeted anti-cancer gene-therapy agent that is being developed to
treat a wide range of solid tumors. It is conveniently administered
as an IV infusion once every two months. It has been observed to be
well-tolerated in >300 cancer patients and demonstrated activity
signals in a VBL-sponsored “all comers” phase 1 trial as well as in
three VBL-sponsored tumor-specific phase 2 studies. Ofranergene
obadenovec is currently being studied in a VBL-sponsored phase 3
potential registration trial for platinum-resistant ovarian
cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024